What is Engine Biosciences?
Engine Biosciences is a Singapore-based biotechnology firm established in 2014. The company leverages machine learning and genomics to accelerate drug discovery processes. By applying advanced computational techniques to biological data, Engine Biosciences aims to identify novel therapeutic targets and develop groundbreaking treatments. Their strategic focus on integrating artificial intelligence with life sciences positions them at the forefront of modern pharmaceutical research and development.
How much funding has Engine Biosciences raised?
Engine Biosciences has raised a total of $88M across 3 funding rounds:
Angel/Seed
$10M
Other Financing Round
$18M
Series A
$60M
Angel/Seed (2018): $10M, investors not publicly disclosed
Other Financing Round (2023): $18M led by Edbi and Polaris Partners
Series A (2023): $60M supported by DHVC, Vectr Ventures, Dimensions Capital, Goodman Capital, Edbi, Baidu Ventures, Polaris Partners, WuXi AppTec, Nest.Bio, WI Harper Group, and Invus
Key Investors in Engine Biosciences
Baidu Ventures
Baidu Ventures is an independent venture fund established in 2017, focusing on spearheading the new age of artificial intelligence. They invest at the forefront of the AI revolution, supporting entrepreneurs in areas from computational genetics to precision medicine, leveraging partnerships and technical expertise.
Edbi
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors since 1991. The company aims to create value and empower businesses to build sustainable legacies through strategic investments in innovative companies.
WI Harper Group
WI Harper Group is a venture capital firm specializing in early-stage investments across multiple sectors, including healthcare and biotechnology. With over 30 years of experience, they support bold entrepreneurs and have a track record of successful IPOs and M&A transactions.
What's next for Engine Biosciences?
The recent major strategic investment signals a pivotal phase for Engine Biosciences, likely enabling significant expansion of its research and development capabilities and potentially accelerating its pipeline towards clinical trials. This influx of capital is expected to fuel further technological advancements in their AI-driven drug discovery platform and solidify strategic partnerships within the pharmaceutical industry. The company's trajectory suggests a strong focus on scaling operations and translating its genomic insights into tangible therapeutic solutions.
See full Engine Biosciences company page
